PT2729474T - Compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo tendo actividade dual como agonistas inversos de h1/antagonistas de 5-ht2a - Google Patents
Compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo tendo actividade dual como agonistas inversos de h1/antagonistas de 5-ht2aInfo
- Publication number
- PT2729474T PT2729474T PT127354090T PT12735409T PT2729474T PT 2729474 T PT2729474 T PT 2729474T PT 127354090 T PT127354090 T PT 127354090T PT 12735409 T PT12735409 T PT 12735409T PT 2729474 T PT2729474 T PT 2729474T
- Authority
- PT
- Portugal
- Prior art keywords
- benzoxazepin
- thieno
- piperazin
- compounds
- inverse agonists
- Prior art date
Links
- -1 (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161505685P | 2011-07-08 | 2011-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2729474T true PT2729474T (pt) | 2018-06-05 |
Family
ID=46513872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT127354090T PT2729474T (pt) | 2011-07-08 | 2012-07-02 | Compostos (tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo tendo actividade dual como agonistas inversos de h1/antagonistas de 5-ht2a |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9481688B2 (enExample) |
| EP (1) | EP2729474B1 (enExample) |
| JP (1) | JP6050813B2 (enExample) |
| KR (1) | KR101582429B1 (enExample) |
| CN (1) | CN103703008B (enExample) |
| AU (1) | AU2012283035B2 (enExample) |
| BR (1) | BR112014000379A2 (enExample) |
| CA (1) | CA2840217C (enExample) |
| DK (1) | DK2729474T3 (enExample) |
| EA (1) | EA023460B1 (enExample) |
| ES (1) | ES2665035T3 (enExample) |
| HR (1) | HRP20180475T1 (enExample) |
| HU (1) | HUE037649T2 (enExample) |
| IN (1) | IN2014MN00144A (enExample) |
| LT (1) | LT2729474T (enExample) |
| MX (1) | MX341132B (enExample) |
| NO (1) | NO2729474T3 (enExample) |
| PL (1) | PL2729474T3 (enExample) |
| PT (1) | PT2729474T (enExample) |
| RS (1) | RS57207B1 (enExample) |
| SI (1) | SI2729474T1 (enExample) |
| WO (1) | WO2013009517A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2943498T3 (pl) * | 2013-01-14 | 2018-01-31 | Lilly Co Eli | Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe jako odwrotni agoniści h1 / antagoniści 5-ht2a o podwójnej aktywności |
| TW201625644A (zh) | 2014-04-29 | 2016-07-16 | 美國禮來大藥廠 | 作為選擇性５－ＨＴＡ反向促效劑之（噻吩并［２，３－ｂ］［１，５］苯并氧氮呯－４－基）哌嗪－１－基化合物 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| CN108371660B (zh) * | 2017-12-14 | 2020-03-10 | 五邑大学 | 一种四氢环戊二烯并吡咯化合物及其衍生物的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| AU775299B2 (en) * | 1999-09-29 | 2004-07-29 | Eli Lilly And Company | Piperidine derivatives as reuptake inhibitors |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
| BRPI0808828A8 (pt) * | 2007-03-15 | 2017-11-28 | Aryx Therapeutics Inc | Compostos de dibenzo[b,f][1,4]oxazapina |
| JP6106361B2 (ja) * | 2008-05-27 | 2017-03-29 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 睡眠障害および他の障害のための方法および組成物 |
| GB0910009D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxo Group Ltd | Novel compounds |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| AU2012300451B2 (en) * | 2011-08-30 | 2016-10-13 | Eli Lilly And Company | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT 2A antagonists |
-
2012
- 2012-07-02 DK DK12735409.0T patent/DK2729474T3/en active
- 2012-07-02 JP JP2014519227A patent/JP6050813B2/ja active Active
- 2012-07-02 LT LTEP12735409.0T patent/LT2729474T/lt unknown
- 2012-07-02 WO PCT/US2012/045254 patent/WO2013009517A1/en not_active Ceased
- 2012-07-02 PT PT127354090T patent/PT2729474T/pt unknown
- 2012-07-02 CA CA2840217A patent/CA2840217C/en not_active Expired - Fee Related
- 2012-07-02 US US14/125,320 patent/US9481688B2/en active Active
- 2012-07-02 AU AU2012283035A patent/AU2012283035B2/en not_active Ceased
- 2012-07-02 HR HRP20180475TT patent/HRP20180475T1/hr unknown
- 2012-07-02 KR KR1020147000119A patent/KR101582429B1/ko not_active Expired - Fee Related
- 2012-07-02 MX MX2014000337A patent/MX341132B/es active IP Right Grant
- 2012-07-02 PL PL12735409T patent/PL2729474T3/pl unknown
- 2012-07-02 HU HUE12735409A patent/HUE037649T2/hu unknown
- 2012-07-02 BR BR112014000379A patent/BR112014000379A2/pt not_active IP Right Cessation
- 2012-07-02 EA EA201391706A patent/EA023460B1/ru not_active IP Right Cessation
- 2012-07-02 CN CN201280031201.7A patent/CN103703008B/zh active Active
- 2012-07-02 RS RS20180568A patent/RS57207B1/sr unknown
- 2012-07-02 EP EP12735409.0A patent/EP2729474B1/en active Active
- 2012-07-02 NO NO12735409A patent/NO2729474T3/no unknown
- 2012-07-02 ES ES12735409.0T patent/ES2665035T3/es active Active
- 2012-07-02 SI SI201231263T patent/SI2729474T1/en unknown
-
2014
- 2014-01-23 IN IN144MUN2014 patent/IN2014MN00144A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2729474B1 (en) | 2018-03-14 |
| ES2665035T3 (es) | 2018-04-24 |
| EP2729474A1 (en) | 2014-05-14 |
| NO2729474T3 (enExample) | 2018-08-11 |
| JP6050813B2 (ja) | 2016-12-21 |
| PL2729474T3 (pl) | 2018-08-31 |
| SI2729474T1 (en) | 2018-04-30 |
| CA2840217A1 (en) | 2013-01-17 |
| MX2014000337A (es) | 2014-11-13 |
| EA023460B1 (ru) | 2016-06-30 |
| RS57207B1 (sr) | 2018-07-31 |
| CA2840217C (en) | 2016-03-22 |
| LT2729474T (lt) | 2018-05-10 |
| CN103703008A (zh) | 2014-04-02 |
| KR20140029512A (ko) | 2014-03-10 |
| KR101582429B1 (ko) | 2016-01-04 |
| HUE037649T2 (hu) | 2018-09-28 |
| JP2014518280A (ja) | 2014-07-28 |
| MX341132B (es) | 2016-08-09 |
| US20140121199A1 (en) | 2014-05-01 |
| HRP20180475T1 (hr) | 2018-06-15 |
| WO2013009517A1 (en) | 2013-01-17 |
| AU2012283035B2 (en) | 2015-07-30 |
| EA201391706A1 (ru) | 2014-04-30 |
| US9481688B2 (en) | 2016-11-01 |
| IN2014MN00144A (enExample) | 2015-06-19 |
| AU2012283035A1 (en) | 2014-01-16 |
| DK2729474T3 (en) | 2018-05-22 |
| BR112014000379A2 (pt) | 2017-01-10 |
| CN103703008B (zh) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201400874B (en) | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | |
| IL266285A (en) | Methods for the production of tian compounds [d - 3,2] pyrimidine | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| PL2857404T3 (pl) | POCHODNE IMIDAZO[1,2-b]PIRYDAZYNY JAKO INHIBITORY KINAZY | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| SG11201402197UA (en) | [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 | |
| IL232304A (en) | [3,2,1] triazolo [5,4– d] pyrimidine derivatives as cannabinoid receptor type 2 agonists [3,2,1] triazolo [5,4– d] pyrimidine as cannabinoid receptor 2 agonists | |
| IL232717B (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| SG11201408816QA (en) | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| LT2729474T (lt) | (tieno[2,3-b][1,5]benzoksazepin-4-il)piperazin-1-ilo junginiai kaip dvigubo aktyvumo h1 inversiniai agonistai/5-ht2a antagonistai | |
| SG11201500883YA (en) | 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| SI2683719T1 (sl) | SUBSTITUIRANE SPOJINE ((5H-PIROLO(2,1-c) (1,4)BENZODIAZEPIN-11-IL)PIPERAZIN-1-IL)2,2-DIMETILPROPANOJSKE KISLINE KOT DVOJNO AKTIVNI H1 INVERZNI AGONISTI/5-HT2A ANTAGONISTI | |
| ZA201504041B (en) | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists | |
| PL390846A1 (pl) | Pochodne 5,11-dimetylo-5H-indolo[2,3-b]chinoliny |